Eberling JL - Search Results

1

The immunophilin ligand GPI-1046 does not have neuroregenerative effects in MPTP-treated monkeys.

Eberling JL, Pivirotto P, Bringas J, Steiner JP, Kordower JH, Chu Y, Emborg ME, Bankiewicz KS. Eberling JL, et al. Exp Neurol. 2002 Dec;178(2):236-42. doi: 10.1006/exnr.2002.8023. Exp Neurol. 2002. PMID: 12504882

2

Dopamine transporter loss and clinical changes in MPTP-lesioned primates.

Eberling JL, Bankiewicz KS, Pivirotto P, Bringas J, Chen K, Nowotnik DP, Steiner JP, Budinger TF, Jagust WJ. Eberling JL, et al. Brain Res. 1999 Jun 19;832(1-2):184-7. doi: 10.1016/s0006-8993(99)01491-2. Brain Res. 1999. PMID: 10375668

3

Tremor is associated with PET measures of nigrostriatal dopamine function in MPTP-lesioned monkeys.

Eberling JL, Pivirotto P, Bringas J, Bankiewicz KS. Eberling JL, et al. Exp Neurol. 2000 Oct;165(2):342-6. doi: 10.1006/exnr.2000.7470. Exp Neurol. 2000. PMID: 10993693

4

Comparison of two methods for the analysis of [18F]6-fluoro-L-m-tyrosine PET data.

Eberling JL, Pivirotto P, Bringas J, Bankiewicz KS. Eberling JL, et al. Neuroimage. 2004 Sep;23(1):358-63. doi: 10.1016/j.neuroimage.2004.06.005. Neuroimage. 2004. PMID: 15325383

5

Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys.

Bankiewicz KS, Daadi M, Pivirotto P, Bringas J, Sanftner L, Cunningham J, Forsayeth JR, Eberling JL. Bankiewicz KS, et al. Among authors: eberling jl. Exp Neurol. 2006 Feb;197(2):363-72. doi: 10.1016/j.expneurol.2005.10.022. Epub 2005 Dec 9. Exp Neurol. 2006. PMID: 16337943 Free PMC article.

6

A novel MPTP primate model of Parkinson's disease: neurochemical and clinical changes.

Eberling JL, Jagust WJ, Taylor S, Bringas J, Pivirotto P, VanBrocklin HF, Bankiewicz KS. Eberling JL, et al. Brain Res. 1998 Sep 14;805(1-2):259-62. doi: 10.1016/s0006-8993(98)00710-0. Brain Res. 1998. PMID: 9733979

7

Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach.

Bankiewicz KS, Eberling JL, Kohutnicka M, Jagust W, Pivirotto P, Bringas J, Cunningham J, Budinger TF, Harvey-White J. Bankiewicz KS, et al. Among authors: eberling jl. Exp Neurol. 2000 Jul;164(1):2-14. doi: 10.1006/exnr.2000.7408. Exp Neurol. 2000. PMID: 10877910

8

Results from a phase I safety trial of hAADC gene therapy for Parkinson disease.

Eberling JL, Jagust WJ, Christine CW, Starr P, Larson P, Bankiewicz KS, Aminoff MJ. Eberling JL, et al. Neurology. 2008 May 20;70(21):1980-3. doi: 10.1212/01.wnl.0000312381.29287.ff. Epub 2008 Apr 9. Neurology. 2008. PMID: 18401019 Clinical Trial.

9

Safety and tolerability of putaminal AADC gene therapy for Parkinson disease.

Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA, VanBrocklin HF, Wright JF, Bankiewicz KS, Aminoff MJ. Christine CW, et al. Among authors: eberling jl. Neurology. 2009 Nov 17;73(20):1662-9. doi: 10.1212/WNL.0b013e3181c29356. Epub 2009 Oct 14. Neurology. 2009. PMID: 19828868 Free PMC article. Clinical Trial.

10

Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes.

Oiwa Y, Eberling JL, Nagy D, Pivirotto P, Emborg ME, Bankiewicz KS. Oiwa Y, et al. Among authors: eberling jl. Front Biosci. 2003 Sep 1;8:a155-66. doi: 10.2741/1104. Front Biosci. 2003. PMID: 12957824

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

73 results

Search Page